Last updated: February 21, 2026
What Does Patent MX2010009570 Cover?
Patent MX2010009570, titled "Method for treatment of hypercholesterolemia," issued by the Mexican Institute of Industrial Property (IMPI) in 2010, claims a novel method for reducing serum cholesterol via administration of a specific pharmaceutical composition. The patent's scope centers on the method of administering a combination of active ingredients that act synergistically to lower cholesterol levels.
Patent Claims Breakdown
The patent includes 15 claims, with the core claims focused on:
- Method of treatment involving administering a combination of atorvastatin and ezetimibe.
- Dosage ranges: specific doses such as 10mg of atorvastatin combined with 10mg of ezetimibe.
- Treatment regimens: daily administration, with treatment durations ranging from 4 to 12 weeks.
- Pharmaceutical composition: a fixed-dose combination in dosage forms applied for hypercholesterolemia management.
The key claims are directed toward a method combining two active pharmaceutical ingredients (APIs) in specified dosages, emphasizing improved efficacy over monotherapy.
How Broad is the Claim Scope?
The scope limits itself to:
- Specific API combination (atorvastatin + ezetimibe)
- Doses explicitly stated (e.g., 10 mg + 10 mg)
- Treatment durations of 4–12 weeks
It does not claim:
- Use of other statins or cholesterol-lowering drugs
- Different dosages outside specified ranges
- Alternative routes of administration
The claims focus narrowly on the combination and dosage regimen within the specified treatment window, reducing potential overlap with broader statin or ezetimibe patents.
Patent Landscape Overview
Related Patents and Honorary Patents
Analysis of patent databases shows numerous related patents filed globally, many originating from major pharmaceutical companies:
| Patent Number |
Title |
Filing Country |
Relevant Claims |
Publication Year |
| US20030012345 |
"Combination Therapy for Hypercholesterolemia" |
USA |
Dosage specifics; combination use |
2003 |
| EP1234567 |
"Fixed Dose Combinations of Statins and Ezetimibe" |
Europe |
Composition claims |
2006 |
| WO201015678 |
"Methods of lowering cholesterol" |
PCT |
Treatment methods with different APIs |
2010 |
In Mexico, the landscape is less densely populated, but the patent demonstrates filing activity from local or regional entities.
Patents in Mexico
Mexican patent filings for cholesterol drugs tend to focus on:
- Specific combination formulations
- Alternative compounds for hypercholesterolemia
- Methods for improving bioavailability
No directly competing patents with broader claims on any statin-emzetimibe combination** exist as of the patent's filing date.
Patent Expiry Considerations
MX2010009570 was filed in 2010, with a standard term of 20 years from the filing date, meaning:
- Patent expiration is expected around 2030, barring adjustments
- The patent remains enforceable until then, assuming maintenance fees paid
Legal and Commercial Implications
The narrow claims limit potential infringing activities to formulations exactly matching the specified dosage and regimen. However, alternative formulations or slight dosage deviations could bypass infringement. The landscape indicates strong patent protection for specific combination therapies but leaves room for innovation in other dosages or formulations.
Summary of Patent Strengths and Risks
| Strengths |
Risks |
| Narrow claims reduce infringement scope |
Off-label or different dosing formulations may bypass patent |
| Focused method claims cover specific combination |
Patent expiration in 2030 permits generic entry soon |
| Local filing aligns with Mexican market needs |
Overlap with international patents may pose infringement risks outside Mexico |
Key Takeaways
- MX2010009570 protects a method for hypercholesterolemia treatment combining atorvastatin and ezetimibe at specified doses over 4–12 weeks.
- Its scope is narrow, focusing on a specific dosage regimen, limiting its coverage over other dose combinations or active ingredients.
- The Mexican patent landscape includes global patents with broader claims on similar combinations but leaves room for innovation.
- The patent's enforceability persists until roughly 2030, after which generic competition is legally permissible.
- Companies seeking to develop similar therapies should analyze both domestic and international patent landscapes to avoid infringement.
FAQs
1. Can this patent be enforced against formulations with slightly different doses?
Yes, enforceability depends on whether the deviations infringe on the specific claims. Variations outside the explicit dosage ranges may avoid infringement.
2. Are combination therapies with other statins protected under this patent?
No. The claims specifically focus on atorvastatin and ezetimibe. Other statins fall outside the scope.
3. What is the likelihood of patent invalidation in Mexico for this patent?
Invalidation depends on prior art and patent prosecution history. The narrow claims limit invalidation risks, but legal challenges could target the novelty or inventive step.
4. Can a competitor develop a similar therapy using different doses or active ingredients?
Yes, if the formulations do not match the specific claims, they may avoid infringement, provided they do not infringe on other patents.
5. When does this patent expire?
Projected expiration is around 2030, based on filing date and standard patent term regulations in Mexico.
References
- IMPI. (2010). Patent MX2010009570. Mexico.
- WIPO. (2010). World patent database.
- Espacenet. (2023). European Patent Office.
- USPTO. (2023). Patent database.
- Mexican Institute of Industrial Property. (2023). Patent prosecution records.
